Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
accurate, achievement, analyst, analyze, bidder, chemotherapy, comparison, competition, competitive, confidence, confidential, delisted, Delisting, docetaxel, drop, examination, examining, exclusion, Franchise, FTB, Germany, investor, IRS, Johnson, loan, loaned, longer, lose, mandatory, notified, OCI, October, Penzberg, people, Perjeta, pertuzumab, plant, prevail, resolution, seller, submission, technical, unrecognized, unsuccessful
Removed:
implied
Filing tables
Filing exhibits
Related press release
PDLI similar filings
Filing view
External links
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(dollars in thousands except ratios)
For the Years Ended December 31, | For the Six Months Ended | |||||||||||||||||||||||
2007 | 2008 | 2009 | 2010 | 2011 | June 30, 2012 | |||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Income before income taxes | $ | 191,073 | $ | 243,334 | $ | 280,285 | $ | 150,370 | $ | 307,428 | $ | 175,103 | ||||||||||||
Add: fixed charges | 16,267 | 14,285 | 19,430 | 43,578 | 36,153 | 16,603 | ||||||||||||||||||
Earnings | $ | 207,340 | $ | 257,619 | $ | 299,715 | $ | 193,948 | $ | 343,581 | $ | 191,706 | ||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense | $ | 16,200 | $ | 14,219 | $ | 19,357 | $ | 43,529 | $ | 36,102 | $ | 16,573 | ||||||||||||
Estimated interest portion of rent expense | 67 | 66 | 73 | 49 | 51 | 30 | ||||||||||||||||||
Fixed charges | $ | 16,267 | $ | 14,285 | $ | 19,430 | $ | 43,578 | $ | 36,153 | $ | 16,603 | ||||||||||||
Ratio of earnings to fixed charges | 12.75 | 18.03 | 15.43 | 4.45 | 9.50 | 11.55 |